Literature DB >> 2153383

Characterization of cyclic nucleotide phosphodiesterases from cultured bovine aortic endothelial cells.

C Lugnier1, V B Schini.   

Abstract

Experiments were carried out in order to isolate and characterize the cyclic nucleotide phosphodiesterase activities in primary and low passages of cultured bovine aortic endothelial cells. The subcellular characterization of the cyclic nucleotide hydrolytic activity showed that both cAMP and cGMP hydrolytic activities were predominant in the cytosolic rather than the particulate fraction of the endothelial cell homogenate. At a low substrate concentration (0.25 microM), the major hydrolytic activity was for cAMP while at a high concentration (20 microM) it was for both cAMP and cGMP. Both cAMP and cGMP hydrolytic activities were insensitive to calmodulin. Cytosolic cyclic nucleotide phosphodiesterase activity was resolved into two distinct phosphodiesterase forms using HPLC. The first eluted form was designated cGS-PDE: it hydrolysed both cAMP and cGMP and its cAMP hydrolytic activity was markedly enhanced by the presence of cGMP. The second form was designated cAMP-PDE: it selectively hydrolysed cAMP. The cytosolic cAMP-PDE was inhibited by micromolar concentrations of cAMP-PDE inhibitors such as trequinsin, rolipram, dipyridamole or papaverine. The cGS-PDE was inhibited by micromolar concentrations of trequinsin, dipyridamole and papaverine and was insensitive to rolipram, except for the hydrolysis of cAMP which was inhibited in the micromolar range. Both the cAMP-PDE and the cGS-PDE were relatively insensitive to the selective cGMP-PDE inhibitor, zaprinast which was about 750-fold less potent on endothelial PDEs than on smooth muscle cGMP-PDE. The identification of selective and specific PDE inhibitors of the different PDE forms may allow a better understanding of the regulation and the role of cyclic nucleotides in endothelial cells.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2153383     DOI: 10.1016/0006-2952(90)90650-a

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  23 in total

1.  Species differences in localization of cardiac cAMP-phosphodiesterase activity: a cytochemical study.

Authors:  L Okruhlicová; N Tribulová; J Styk; A Eckly; C Lugnier; J Slezk
Journal:  Mol Cell Biochem       Date:  1997-08       Impact factor: 3.396

Review 2.  Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments.

Authors:  Thérèse Keravis; Claire Lugnier
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

Review 3.  PDE1 isozymes, key regulators of pathological vascular remodeling.

Authors:  Stefan Chan; Chen Yan
Journal:  Curr Opin Pharmacol       Date:  2011-09-29       Impact factor: 5.547

4.  Blood cells and endothelial barrier function.

Authors:  Stephen F Rodrigues; D Neil Granger
Journal:  Tissue Barriers       Date:  2015-04-03

5.  Comparative study of the vasorelaxant activity, superoxide-scavenging ability and cyclic nucleotide phosphodiesterase-inhibitory effects of hesperetin and hesperidin.

Authors:  Francisco Orallo; Ezequiel Alvarez; Hélène Basaran; Claire Lugnier
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-11-17       Impact factor: 3.000

6.  Endothelium-dependent and independent relaxation of the rat aorta by cyclic nucleotide phosphodiesterase inhibitors.

Authors:  N Komas; C Lugnier; J C Stoclet
Journal:  Br J Pharmacol       Date:  1991-10       Impact factor: 8.739

7.  Role of cyclic AMP in promoting the thromboresistance of human endothelial cells by enhancing thrombomodulin and decreasing tissue factor activities.

Authors:  G Archipoff; A Beretz; K Bartha; C Brisson; C de la Salle; C Froget-Léon; C Klein-Soyer; J P Cazenave
Journal:  Br J Pharmacol       Date:  1993-05       Impact factor: 8.739

8.  Hyperpermeability of pulmonary endothelial monolayer: protective role of phosphodiesterase isoenzymes 3 and 4.

Authors:  N Suttorp; P Ehreiser; S Hippenstiel; M Fuhrmann; M Krüll; H Tenor; C Schudt
Journal:  Lung       Date:  1996       Impact factor: 2.584

9.  Effect of theophylline on beta-adrenergic receptor density and cAMP content in bovine aortic smooth muscle cells.

Authors:  K Graf; U Dümmler; M Grfe; A O'Connor; E Fleck; G Kunkel
Journal:  Inflamm Res       Date:  1995-08       Impact factor: 4.575

10.  cAMP-specific phosphodiesterase inhibitor, rolipram, reduces eosinophil infiltration evoked by leukotrienes or by histamine in guinea pig conjunctiva.

Authors:  S J Newsholme; L Schwartz
Journal:  Inflammation       Date:  1993-02       Impact factor: 4.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.